New drug cocktail shows promise for tough leukemia
NCT ID NCT04188405
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 21 times
Summary
This study tests a combination of three drugs (decitabine, venetoclax, and ponatinib) in 20 people with a rare, aggressive leukemia called Philadelphia chromosome-positive acute myeloid leukemia or chronic myelogenous leukemia in blast phase. The goal is to see if the drugs can shrink or control the cancer. Participants take the drugs by mouth or IV, and the study tracks how many achieve remission after two treatment cycles.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.